US 20210308206A1

(19) United States

(12) Patent Application Publication

(10) Pub. No.: US 2021/0308206 A1

(43) Pub. Date: Oct. 7, 2021

Kumar et al.

(54) **ACTIVIN TYPE 2 RECEPTOR BINDING PROTEINS AND USES THEREOF**

(71) Applicant: **Acceleron Pharma Inc.**, Cambridge, MA (US)

(72) Inventors: **Ravindra Kumar**, Acton, MA (US); **Jonathan Belk**, Lebanon, NH (US); **Asya Grinberg**, Lexington, MA (US); **Dianne Sako**, Medford, MA (US); **Roselyne Castonguay**, Watertown, MA (US)

(21) Appl. No.: **17/231,981**

(22) Filed: **Apr. 15, 2021**

Related U.S. Application Data

(63) Continuation of application No. 16/390,394, filed on Apr. 22, 2019, now Pat. No. 11,000,565, which is a continuation of application No. 15/456,392, filed on Mar. 10, 2017, now Pat. No. 10,307,455.

(60) Provisional application No. 62/306,354, filed on Mar. 10, 2016.

Publication Classification

(51) **Int. Cl.**

A61K 38/02	(2006.01)
C07K 16/28	(2006.01)
A61K 38/16	(2006.01)
C07K 14/00	(2006.01)
C07K 14/47	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/02*** (2013.01); ***C07K 16/2863*** (2013.01); ***A61K 38/16*** (2013.01); ***C07K 14/001*** (2013.01); ***C07K 14/47*** (2013.01); *A61K 38/00* (2013.01); *C07K 2317/76* (2013.01); *C07K 2317/55* (2013.01); *C07K 2317/21* (2013.01); *C07K 2317/34* (2013.01); *C07K 2317/92* (2013.01)

(57) **ABSTRACT**

This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Specification includes a Sequence Listing.